These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4227 related items for PubMed ID: 15466214

  • 1. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 2. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C.
    Cancer Res; 2003 Nov 01; 63(21):7106-12. PubMed ID: 14612503
    [Abstract] [Full Text] [Related]

  • 3. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
    Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC.
    Oncogene; 2003 Aug 28; 22(36):5602-13. PubMed ID: 12944908
    [Abstract] [Full Text] [Related]

  • 4. Androgens activate mitogen-activated protein kinase via epidermal growth factor receptor/insulin-like growth factor 1 receptor in the mouse PC-1 cell line.
    Hamzeh M, Robaire B.
    J Endocrinol; 2011 Apr 28; 209(1):55-64. PubMed ID: 21220406
    [Abstract] [Full Text] [Related]

  • 5. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 6. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
    Mukherjee B, Mayer D.
    Int J Oncol; 2008 Sep 01; 33(3):623-9. PubMed ID: 18695894
    [Abstract] [Full Text] [Related]

  • 7. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM, Shen R.
    Oncogene; 2006 Mar 30; 25(14):2011-21. PubMed ID: 16434977
    [Abstract] [Full Text] [Related]

  • 8. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C.
    Cancer Res; 2002 Nov 01; 62(21):6039-44. PubMed ID: 12414626
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May 01; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

  • 10. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG, Musti AM, Lanzino M, Panno ML, Turano E, Zumpano R, Belfiore A, Andò S, Maggiolini M.
    Int J Biochem Cell Biol; 2009 Mar 01; 41(3):603-14. PubMed ID: 18692155
    [Abstract] [Full Text] [Related]

  • 11. 17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells.
    Pandini G, Genua M, Frasca F, Squatrito S, Vigneri R, Belfiore A.
    Cancer Res; 2007 Sep 15; 67(18):8932-41. PubMed ID: 17875736
    [Abstract] [Full Text] [Related]

  • 12. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y, Wolff DW, Lin MF, Tu Y.
    Mol Pharmacol; 2007 Jul 15; 72(1):73-85. PubMed ID: 17430995
    [Abstract] [Full Text] [Related]

  • 13. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N.
    Prostate; 2008 Feb 15; 68(3):287-95. PubMed ID: 18163430
    [Abstract] [Full Text] [Related]

  • 14. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ.
    Mol Cell Endocrinol; 2004 May 31; 220(1-2):109-23. PubMed ID: 15196705
    [Abstract] [Full Text] [Related]

  • 15. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G, Mineo R, Frasca F, Roberts CT, Marcelli M, Vigneri R, Belfiore A.
    Cancer Res; 2005 Mar 01; 65(5):1849-57. PubMed ID: 15753383
    [Abstract] [Full Text] [Related]

  • 16. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
    Iacopino F, Lama G, Angelucci C, Sica G.
    Int J Oncol; 2006 Jul 01; 29(1):237-47. PubMed ID: 16773205
    [Abstract] [Full Text] [Related]

  • 17. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
    Wang LG, Ossowski L, Ferrari AC.
    Cancer Res; 2001 Oct 15; 61(20):7544-51. PubMed ID: 11606392
    [Abstract] [Full Text] [Related]

  • 18. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
    Lin J, Adam RM, Santiestevan E, Freeman MR.
    Cancer Res; 1999 Jun 15; 59(12):2891-7. PubMed ID: 10383151
    [Abstract] [Full Text] [Related]

  • 19. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF, Wang Y, Cho JY, Libermann TA.
    Cancer Res; 2003 May 01; 63(9):2206-15. PubMed ID: 12727841
    [Abstract] [Full Text] [Related]

  • 20. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC, Astapova I, Hollenberg AN, Balk SP.
    Cancer Res; 2007 Sep 01; 67(17):8388-95. PubMed ID: 17804755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 212.